Market revenue in 2023 | USD 1.3 million |
Market revenue in 2030 | USD 2.6 million |
Growth rate | 10.2% (CAGR from 2023 to 2030) |
Largest segment | Pure prp |
Fastest growing segment | Leukocyte Rich PRP |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pure PRP, Leukocyte Rich PRP |
Key market players worldwide | Johnson & Johnson, Arthrex, Terumo Corp, Zimmer Biomet Holdings Inc, Stryker Corp, EmCyte Corporation, Dr. PRP USA, Juventix Regenerative Medical, APEX Biologix, Celling Biosciences |
Pure prp was the largest segment with a revenue share of 53.85% in 2023. Horizon Databook has segmented the Norway platelet rich plasma (prp) market based on pure prp, leukocyte rich prp covering the revenue growth of each sub-segment from 2018 to 2030.
Musculoskeletal disorders have a significant financial burden on the Norwegian healthcare system. PRP therapy, as part of the treatment network, has gained prominence in addressing these issues.
The demand for PRP treatments is expected to contribute to market growth in Norway, offering a promising avenue for patients seeking effective and minimally invasive solutions for musculoskeletal conditions while alleviating the strain on the healthcare system.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account